Nestlé has doubled down on its bet on a new therapy for peanut allergies.
Nestlé has doubled down on its bet on a new therapy for peanut allergies.
Palforzia, from Aimmune Therapeutics Inc., treats peanut allergies by reducing the trauma suffered by allergic individuals upon exposure to peanuts. A powder made from peanuts, Palforzia is administered in escalating doses over an 11-month period. It does not cure peanut allergies, and sufferers must continue to avoid peanuts, but it mitigates the potentially fatal consequences of peanut exposure.
The FDA approvedPalforzia on Jan. 31, and Aimmune announced on Feb. 5 that Nestlé had investedanother $200 million in the drug. Nestlé had previously made investments totaling $273 million.
Nestlé’s involvement is seen as a way to increase revenue from its Health Science division and pivot away from food, where sales have stagnated.
Kaeser is the world’s leading air systems specialist and offers a full range of compressed air solutions for almost any application. From industrial compress...
Take a moment to see the scope of Kaeser's commitment to innovative system designs that guarantee ultra-reliable compressed air, easy maintenance, and greater efficiency.
Ventilation has a huge impact on the ambient temperature in the compressor room and is often the missing link to temperature regulation issues. Here are four factors to consider...
Learn how to get a smart, reliable, energy-efficient compressed air system delivered in a turnkey, weatherproof and temperature-controlled enclosure that needs little or no onsite...
